Nicotine and Cannabis Vape Labeling Experiment - Spring 2025
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Apr 4, 2025
Trial Information
Current as of November 08, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study, called the Nicotine and Cannabis Vape Labeling Experiment (EPIC/ADVANCE), asks how the label on a vaping device and the device’s color/flavor might change teens’ interest in trying vaping, what they think about health risks, and what effects they expect. In a randomized setup, participants are assigned to one of seven label options (for example plain, “contains nicotine,” or “contains THC”) and one of three colors/flavors (mint, white/original, or blue/blueberry). They’ll see a vape image with that labeling and color, and then answer short questions. It’s a one-time, survey-based activity, not a real-use test.
Who can join: youths aged 11–19 who are current students at a partnering high school, are considered healthy, and can understand consent and the surveys. Both boys and girls can participate. Participants won’t be given any vaping product; the study focuses on opinions and perceptions gathered from brief, about-5-minute surveys (several measures totaling roughly 20 minutes). The trial is sponsored by the University of Southern California with collaboration from NIDA and NCI, led by Adam Leventhal, and is currently enrolling with about 3,900 participants planned, aiming to wrap up around May 2025.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must be enrolled in a partnering high school.
- Exclusion Criteria:
- • Participants who cannot independently understand study consent and the study surveys are ineligible.
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported